Research
Treating Central Nervous System Tumors with MK-0752
MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies
Protocol Description
This multi-center Phase I study is studying MK-0752 in patients with progressive or refractory primary central nervous system (CNS) tumors. Prior studies reveal that this new drug appears to block an enzyme that may be involved in brain tumor development. Through this study, researchers will investigate optimum dosages and gain a better understanding of side effects, benefits and how the body processes the drug.
Eligibility Criteria
Patients of both genders, ages 3 to 21, who have been diagnosed with a recurrent or progressive brain tumor that have been unable to be cured by any known standard treatment will be asked to participate.
Boys: Ages 3 to 21
Girls: Ages 3 to 21
Requirements
After an initial examination, patients will be given the drug orally once a day for three days with the following four days off for a total of four weeks, which is known as a course. Patients may continue on study for up to 18 months.
Frequency of visits: Weekly for 1 month; every 4 weeks thereafter
Duration: Up to 18 months
Status: Open for Enrollment
Sources of Support
Pediatric Brain Tumor Consortium
National Cancer Institute
Additional Resources
Study description at National Institutes of Health
Primary Investigator(s)
Regina Jakacki, MD
Contact Information
To get started, please contact:
Sharon DiBridge, CRA
412-692-7070
Angela Krol, Research RN, BSN
412-692-8047
